Pharmacotherapy for Postprandial Hyperglycemia in Type 2 Diabetes.

Yoo,  Hye Jin

doi:2012.13.1.39

J Korean Diabetes > Volume 13(1); 2012 > Article

Focused Issue

The Journal of Korean Diabetes 2012;13(1):39-43.
DOI: https://doi.org/10.4093/jkd.2012.13.1.39 Published online March 31, 2012.

식후 고혈당의 약물요법

류혜진

Pharmacotherapy for Postprandial Hyperglycemia in Type 2 Diabetes.

Hye Jin Yoo

Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. deisy21@naver.com

Abstract

A growing body of evidence shows that effective postprandial hyperglycemia management in individuals with type 2 diabetes can reduce the risk of diabetic complications and cardiovascular diseases. Therefore, accurate monitoring and effective intervention for postprandial hyperglycemia is very important in routine clinical practice for type 2 diabetes. Therapeutic modalities for the management of postprandial hyperglycemia include oral antidiabetic drugs (alpha glucosidase inhibitor, meglitinide, dipeptidyl peptidase-IV inhibitor), ultra-short-acting insulin analogues, and incretin mimetics. A detailed understanding of the advantages and disadvantages of various pharmacotherapies and a careful understanding of the underlying physical and social situations of each patient will be of great help to determine the appropriate prescription for postprandial hyperglycemia management.

Key Words: Hyperglycemia, Type 2 diabetes mellitus, Drug therapy